Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gene Colice

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Advances in Therapy|September 18, 2023
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR StudyAndrew Menzies-Gow, Christopher S Ambrose, Gene Colice, et al.
Allergy|December 16, 2021
Baseline type 2 biomarker levels and response to tezepelumab in severe asthmaJonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, et al.
Respiratory Research|November 16, 2016
Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR studyStefan Franzén, Christer Janson, Kjell Larsson, et al.
Pulmonary Therapy|December 8, 2023
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR StudyJeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|December 12, 2022
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR studyJonathan Corren, Christopher S Ambrose, Janet M Griffiths, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|August 17, 2022
Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR studyTamotsu Ishizuka, Andrew Menzies-Gow, Hiroshi Okada, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 14, 2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthmaJonathan Corren, Michael E Wechsler, Geoffrey Chupp, et al.
Respiratory Research|October 14, 2020
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthmaClaire Emson, Sarah Diver, Latifa Chachi, et al.
Pragmatic and Observational Research|December 15, 2017
The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationshipGene Colice, David Price, Maria Gerhardsson de Verdier, et al.
The European Respiratory Journal|November 17, 2018
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthmaWilliam W Busse, Guy G Brusselle, Stephanie Korn, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Advances in Therapy|September 18, 2023
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR StudyAndrew Menzies-Gow, Christopher S Ambrose, Gene Colice, et al.
Allergy|December 16, 2021
Baseline type 2 biomarker levels and response to tezepelumab in severe asthmaJonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, et al.
Respiratory Research|November 16, 2016
Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR studyStefan Franzén, Christer Janson, Kjell Larsson, et al.
Pulmonary Therapy|December 8, 2023
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR StudyJeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|December 12, 2022
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR studyJonathan Corren, Christopher S Ambrose, Janet M Griffiths, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|August 17, 2022
Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR studyTamotsu Ishizuka, Andrew Menzies-Gow, Hiroshi Okada, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 14, 2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthmaJonathan Corren, Michael E Wechsler, Geoffrey Chupp, et al.
Respiratory Research|October 14, 2020
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthmaClaire Emson, Sarah Diver, Latifa Chachi, et al.
Pragmatic and Observational Research|December 15, 2017
The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationshipGene Colice, David Price, Maria Gerhardsson de Verdier, et al.
The European Respiratory Journal|November 17, 2018
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthmaWilliam W Busse, Guy G Brusselle, Stephanie Korn, et al.
Pageof 7